Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.83 |
| ▸ | KDR | P35968 | 16/20 | 0.83 |
| ▸ | LCK | P06239 | 15/20 | 0.83 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.83 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.83 |
| ▸ | KIT | P10721 | 2/20 | 0.83 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.81 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.81 |
| ▸ | JAK3 | P52333 | 10/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | TYK2 | P29597 | 1/20 | 0.72 |
| ▸ | SYK | P43405 | 1/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.72 |
| ▸ | BTK | Q06187 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505067 | 0.91 | MAPK14 (1.00) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5495638 | 0.90 | MAPK14 (0.78) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5489617 | 0.90 | MAPK14 (0.94) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5498815 | 0.90 | MAPK14 (0.94) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5502145 | 0.89 | MAPK14 (0.76) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5492767 | 0.87 | RIPK1 (0.76) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5496169 | 0.86 | MAPK14 (0.91) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5497210 | 0.86 | MAPK14 (0.72) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5502369 | 0.85 | LCK (0.62) | MAPK14KDRLCKMAPK9MAPK10 | |
| SCHEMBL5494376 | 0.84 | LCK (0.75) | MAPK14KDRLCKMAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | MAPK14 301/4885KDR 1044/4885LCK 106/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | MAPK14 523/4885KDR 569/4885LCK 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.